title: Low HDL-cholesterol: a strong predictor of glycemic response to glitazone treatment in patients with type 2 diabetes.
abstract: We performed a study in 102 people with type 2 diabetes aiming to determine "easy-to-use" predictive factors for glycemic response to glitazones. We found that low baseline HDL-cholesterol (<40 mg/L [1.04 mmol/L] in males, <50 mg/L [1.30 mmol/L] in females) was a strong independent predictor of glycemic response to glitazones (OR=2.67 [2.02-3.52], p=0.0004).
authors.affiliation: Service Endocrinologie, Diabétologie et Maladies Métaboliques, Centre Hospitalier Universitaire de Dijon, France. bruno.verges@chu-dijon.fr
authors.forename: Bruno
authors.initials: B
authors.lastname: Vergès
authors.forename: Laura
authors.initials: L
authors.lastname: Radu
authors.forename: Sabine
authors.initials: S
authors.lastname: Baillot-Rudoni
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Brindisi
authors.forename: Alix
authors.initials: A
authors.lastname: Poussier
authors.forename: Benjamin
authors.initials: B
authors.lastname: Bouillet
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Petit
authors.forename: Laurence
authors.initials: L
authors.lastname: Duvillard
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects; D008076:Cholesterol, HDL / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D011446:Prospective Studies; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D008076:Cholesterol, HDL; D006442:Glycated Hemoglobin; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones